amcure, a spin-off of the Karlsruhe Institute for Technology (KIT), today announces the closing of a Series A financing deal worth a total of EUR 5 million.
The business objective is the development of the new cancer drug AM001, that not only stops the growth of primary tumours, but also prevents the development of metastases, and can induce the regression of metastases that have already developed.
‘It would be an important breakthrough if these observations are confirmed in cancer patients,’ says Dr Katja Rosenkranz, Senior Project Manager at the Spinnovator. ‘Over 90% of cancer patients die from the metastases rather than from the primary tumour.’
Ascenion’s Spinnovator team has actively supported amcure’s founders and will continue to assist with developing the project, together with the private investors involved.
Find out more about the company and its financing in the current newsletter, cover story about amcure. <link file:2267 download>Ascenion Information June 2014
More about <link http: www.amcure.com external-link-new-window>amcure
More about <link http: www.spinnovator.de external-link-new-window>Spinnovator
